Global Atopic Dermatitis Market - 2023-2030

Global Atopic Dermatitis Market - 2023-2030

The global atopic dermatitis market reached US$ 5.8 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 16.5 billion by 2030. The global atopic dermatitis market is expected to exhibit a CAGR of 14.4% during the forecast period (2023-2030). The increasing research and development activities to explore new therapeutic approaches and identify innovative drugs for atopic dermatitis driving up demand for atopic dermatitis market trends.

The atopic dermatitis market is experiencing significant growth worldwide. The global atopic dermatitis market is witnessing a rise in the development of innovative therapies, including biologic agents, targeted topical treatments, and personalized medicine approaches. Biologics, such as monoclonal antibodies, have shown better results in clinical trials by targeting specific immune pathways involved in atopic dermatitis. Additionally, advancements in drug delivery systems and the introduction of novel topical formulations aim to improve convenience, efficacy, and patient compliance.

The atopic dermatitis market is driven by the factors such as the increasing prevalence of atopic dermatitis, increasing demand for novel drugs and treatment options, increasing awareness, growing patient demand for better treatment, and advancements in treatment options.

Market Dynamics

Increasing Demand for Novel Drugs and Treatment Options Drive the Growth of the Atopic Dermatitis Market

The atopic dermatitis market is experiencing significant growth due to the increasing demand for novel drugs and treatment options. Patients and healthcare providers are seeking innovative therapies that can provide better symptom control, long-term management, and improved quality of life for individuals with atopic dermatitis.

One of the primary drivers of market growth is the development of biologic drugs specifically targeting the immune pathways involved in atopic dermatitis. Biologics, such as monoclonal antibodies, have shown promising results in clinical trials by effectively reducing inflammation and itching associated with the condition. These drugs offer a targeted approach with fewer systemic side effects compared to traditional systemic therapies. As a result, the demand for biologics is on the rise, leading to increased investments in research and development by pharmaceutical companies.

For instance, in February 2023, Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved its supplemental New Drug Application (sNDA) for CIBINQO® (abrocitinib), expanding its indication to include adolescents (12 to <18 years) with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable. CIBINQO was previously approved only for the treatment of adults 18 years and older.

Additionally, there is a growing demand for topical formulations with improved efficacy and safety profiles. Patients are looking for convenient, easy-to-use, and non-steroidal alternatives to traditional corticosteroid creams. In response to this demand, pharmaceutical companies are developing advanced topical treatments, including calcineurin and phosphodiesterase-4 inhibitors, which offer targeted action and better long-term management of atopic dermatitis symptoms.

Rising Awareness About Atopic Dermatitis Also Drives the Growth of the Market

Patient advocacy groups, dermatology associations, and healthcare organizations have been actively involved in raising awareness about atopic dermatitis. These groups provide educational resources, and support networks, and promote initiatives to empower patients and their families. Patients becoming more informed about atopic dermatitis makes them more likely to seek appropriate medical attention and explore available treatment options.

Efforts to educate healthcare providers about atopic dermatitis have increased in recent years. Continuing medical education programs, conferences, and research publications have focused on improving the knowledge and understanding of atopic dermatitis among dermatologists, primary care physicians, and other healthcare professionals. Enhanced awareness among healthcare providers leads to better diagnosis, referral to specialists when needed, and appropriate treatment recommendations.

For instance, in March 2023, STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announced the launch of the new XTRAC website, www.xtracclear.com. The new website educates patients on XTRAC excimer laser therapy for the treatment of psoriasis, vitiligo, and atopic dermatitis (eczema).

The High Cost of the Treatment will Hamper the Growth of the Market.

Atopic dermatitis is a chronic condition that may require long-term treatment to manage symptoms effectively. This prolonged duration of treatment can result in significant cumulative costs for patients. Expenses associated with prescription medications, frequent doctor visits, laboratory tests, and supportive care can add up over time, posing financial challenges for individuals and healthcare systems.

Insurance coverage for atopic dermatitis treatments may vary, and some insurance plans may not fully cover the costs of certain medications or therapies. High deductibles, co-pays, and prior authorization requirements can create barriers to accessing expensive treatments. This lack of coverage or limited reimbursement can deter patients from seeking appropriate care or opting for alternative, potentially less effective, and less costly treatment options.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the atopic dermatitis market. Many clinical trials and research activities related to atopic dermatitis have been delayed or put on hold due to the pandemic. The focus of healthcare resources and research efforts has shifted towards addressing COVID-19, diverting attention and resources away from non-COVID-related conditions. This delay in clinical trials and research can impact the development and availability of new treatments for atopic dermatitis in the future.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to moderately impact the global atopic dermatitis market. The conflict can disrupt the supply chains of pharmaceutical products and medical devices, which could affect the availability of atopic dermatitis treatments in affected regions. If manufacturing facilities or transportation routes are disrupted, it may lead to delays in the production, distribution, and availability of medications, affecting patients' access to necessary treatments.

Segment Analysis

The global atopic dermatitis market is segmented based on disease severity, treatment type, distribution channel, and region.

Corticosteroids from the Treatment Type Segment Accounts for 25.6% of the Atopic Dermatitis Market Share

Corticosteroids are widely used in the treatment of atopic dermatitis due to their anti-inflammatory properties, which help to reduce itching, redness, and inflammation associated with the condition. They are available in various formulations, including creams, ointments, lotions, and foams, allowing for topical application to affected areas.

Corticosteroids are considered the mainstay of treatment for atopic dermatitis and are often prescribed as a first-line therapy for mild to moderate cases. They provide rapid relief of symptoms and have a well-established efficacy profile. Their widespread use and effectiveness contribute to their dominant market position.

For instance, in April 2022, At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis (AD) receiving lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference. Lebrikizumab, an investigational IL-13 inhibitor, also showed improvements in itch, sleep interference, and quality of life when combined with TCS, compared to placebo plus TCS.

Geographical Analysis

North America Accounted for Approximately 39.9% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Technological Advancements

North America boasts well-developed healthcare systems with a strong emphasis on dermatology and skin health. The region has a robust network of healthcare facilities, including specialized dermatology clinics, research institutions, and academic centers. This advanced infrastructure enables efficient diagnosis, treatment, and management of atopic dermatitis, attracting patients seeking high-quality care.

North America is at the forefront of technological advancements in healthcare, including in the field of dermatology. Innovative diagnostic tools, imaging techniques, and therapeutic modalities have been widely adopted in the region. Technological advancements, such as telemedicine, electronic health records, and digital health platforms, have facilitated remote consultations, access to medical information, and enhanced patient care management for individuals with atopic dermatitis.

Competitive Landscape

The major global players in the atopic dermatitis market include Pfizer Inc., Allergan Plc., Novartis AG, Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Galderma Inc., Mylan N.V., LEO Pharma Inc., Regeneron Pharmaceuticals Inc., and Valeant Pharmaceuticals.

Why Purchase the Report?
• To visualize the global atopic dermatitis market segmentation based on disease severity, treatment type, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of atopic dermatitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global atopic dermatitis market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies